SomaLogic, Inc.

SomaLogic, Inc. (Nasdaq: SLGC) is a proteomics and life sciences technology company that entered public markets in September 2021 through a de-SPAC merger with CM Life Sciences III Inc., a blank-check vehicle sponsored by CM Life Sciences. The Boulder, Colorado-based firm develops the SomaScan proteomics platform, used for protein biomarker discovery across pharmaceutical research and clinical diagnostics. Its December 21, 2023 Form 8-K filing was submitted during a period in which SomaLogic was actively pursuing a strategic combination with Standard BioTools Inc., a transaction that subsequently closed in early 2024. Investors tracking SLGC and the broader life sciences SPAC universe can sign up for full data and filing analytics at SpacDesk.